Michael V Mandola

Title: Michael V Mandola: Innovator in Cancer Treatment

Introduction

Michael V Mandola is a notable inventor based in Williamstown, NJ (US). He has made significant contributions to the field of cancer treatment, particularly in the area of non-small cell lung cancer (NSCLC). His innovative approach combines chemotherapy with targeted immunotherapy, showcasing his commitment to advancing medical science.

Latest Patents

Michael V Mandola holds a patent for "Methods of treating NSCLC comprising administering platinum doublet chemotherapy followed by an anti-PD-1 antibody and an anti-CTLA-4 antibody." This patent outlines a method for treating patients afflicted with tumors derived from NSCLC. The method involves administering a combination of chemotherapy, an anti-PD-1 antibody or an anti-PD-L1 antibody, and an anti-CTLA-4 antibody. Notably, the chemotherapy is administered for a period shorter than the standard treatment duration. He has 1 patent to his name.

Career Highlights

Michael is currently associated with Bristol-Myers Squibb Company, a leading biopharmaceutical company. His work focuses on developing innovative therapies that improve patient outcomes in oncology. His dedication to research and development has positioned him as a key player in the pharmaceutical industry.

Collaborations

Michael has collaborated with esteemed colleagues, including Sabine Maier and Abderrahim Oukessou. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking treatments.

Conclusion

Michael V Mandola's contributions to cancer treatment through his innovative patent demonstrate his expertise and commitment to improving patient care. His work continues to inspire advancements in the field of oncology.